SCHEMBL30186406

SCHEMBL30186406

C[C@H](NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@@H](N)CCCNC(=N)N)C(=O)N[C@@H](CS)C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ NPY4R P50391 9/20 0.40
▸ NPY5R Q15761 7/20 0.40
▸ NPY1R P25929 6/20 0.40
▸ NPY2R P49146 4/20 0.40
▸ PTGS1 P23219 1/20 0.39
▸ GSTK1 Q9Y2Q3 1/20 0.39
▸ FNTA P49354 2/20 0.39
▸ FNTB P49356 2/20 0.39
▸ PGGT1B P53609 1/20 0.39
▸ OPRL1 P41146 2/20 0.39
▸ IL23R Q5VWK5 1/20 0.38
▸ KEAP1 Q14145 1/20 0.38
▸ NOD1 Q9Y239 1/20 0.37
▸ CXCR4 P61073 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29374559 0.94 PTGS1 (0.43) NPY4RNPY5RNPY1RNPY2RPTGS1
SCHEMBL30186416 0.92 IL23R (0.44) NPY4RNPY5RNPY1RNPY2ROPRL1
SCHEMBL30186441 0.89 NPY4R (0.42) NPY4RNPY5RNPY1RNPY2ROPRL1
SCHEMBL29674881 0.89 NPY4R (0.43) NPY4RNPY5RNPY1RNPY2ROPRL1
SCHEMBL31370850 0.88 OPRL1 (0.44) NPY4RNPY5RNPY1RNPY2ROPRL1
SCHEMBL31411174 0.88 OPRL1 (0.44) NPY4RNPY5RNPY1RNPY2ROPRL1
SCHEMBL31127543 0.88 PTGS1 (0.41) NPY4RNPY5RNPY1RNPY2RPTGS1
SCHEMBL29774681 0.88 NPY4R (0.46) NPY4RNPY5RNPY1RNPY2ROPRL1
SCHEMBL31000882 0.88 PTGS1 (0.45) NPY4RNPY5RNPY1RNPY2RPTGS1
SCHEMBL29372439 0.88 PTGS1 (0.40) NPY4RNPY5RNPY1RNPY2RPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230165943-A1 TP508 ACUTE THERAPY FOR PATIENTS WITH RESPIRATORY VIRUS INFECTION CHRYSALIS BIOTHERAPEUTICS, INC. 2023-06-01 — — US disclosed
EP-4132948-A1 TP508 ACUTE THERAPY FOR PATIENTS WITH RESPIRATORY VIRUS INFECTION Chrysalis Biotherapeutics (US) 2023-02-15 — — EP disclosed
Send feedback